Risk Assessment in PAH.

Slides:



Advertisements
Similar presentations
Marius M Hoeper Therapeutic goals and algorithms.
Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:
Exploring Early Combination Therapy in PAH
Monitoring and Modifying Treatment in PAH
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Risk Stratification in PAH: What Do the Latest Data Suggest?
A Paradigm Shift in PAH.
Objective Assessment of RA: Expanding the Horizons
An Update on Oral Prostanoids: Advancing Care for PAH?
Identifying and Managing Dyspnea Associated With CTEPH
Glaucoma Progression.
UNDERSTANDING RISK STRATIFICATION IN PAH:
The Latest Data on Oral Prostacyclin Therapy in PAH
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
All About PAH:.
How and When to Decide on Revascularization in Stable Ischemic Heart Disease.
Counseling Patients About Germline BRCA Mutations
Decision-making in the eRA of Treating to Target
PAH Therapy Revisited.
PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence
Improving Risk Assessment and Early Diagnosis in PAH
Updates in Pulmonary Arterial Hypertension
Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy
Are We Closer to Personalized Medicine in MS?
WHO Clinical Classification of PH Complex Cases in PH.
Selected Highlights of the Latest Advances in PAH
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Antithrombotic Protection in CAD and HF
Evolving Science of PAH Treatment
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Risk Stratification in CAD and PAD
Examining the Latest Evidence in PAH
Poor Response to Initial Therapy for Migraine
Has the 6-Min Walk Distance Run Its Course?
Personalized Therapy in Relapsed or Refractory CLL
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Oral Prostanoids and PAH
Navigating Treatment Options in PAH
Preventing Clinical Events in PAH
PAH and Prostacyclin Pathways in Focus
When Is Intrathecal Drug Delivery Appropriate?
PAH-Related Morbidity as a Predictor of Mortality
PAH Treatment.
Guide to Atopic Dermatitis
Pulmonary Arterial Hypertension and Connective Tissue Disease
What's New in PAH?.
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
Incorporating Prostacyclins Into Practice
Program Goals Background: Anticoagulation in Patients With VTE.
Perspective on the Multidisciplinary Management of PAH
Live on PAH: Breathing Life Into Patients With PAH
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Optimal Treatment of PAH
When Is Intrathecal Drug Delivery Appropriate?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
Incorporating New PAH Treatments Into Clinical Practice
PAH Pathways: What Do the Data Tell Us?”
Clinical Comparisons in CTEPH
Pulmonary Arterial Hypertension and Hospitalizations
What's New in PAH?.
My PAH Patient.
Presentation transcript:

Risk Assessment in PAH

Case Study: 54-Year-Old Woman Referred for Consultation Because of Abnormal Echo

Exam and Findings

Invasive and Noninvasive Metrics

Determinants of Prognosis in PAH

2015 ESC/ERS Risk Evaluation

SPAHR Risk Stratification

French Registry Low-Risk Criteria

COMPERA Registry Risk Stratification

Summary of 3 European Studies

French Registry BNP Subset Analysis

ESC/ERS 2015 Treatment Algorithm for PAH

The Rationale for Combination Therapy

The Ambrisentan and Tadalafil in Patients With PAH (AMBITION) Trial

Initial Combination Therapy for WHO FC III

3 Month Follow-Up on ERA/PDE5i

Treatment Options

GRIPHON Treatment Effect by Subgroup

Back to the Case

Revisiting the Decision to Stay the Course…

Take-Home Points

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)